Erasca announced the closing of an upsized public offering, selling 25,875,000 shares at $10.00 each and generating gross proceeds of roughly $258.8 million. The clinical‑stage precision oncology company said all offered shares were sold by Erasca to the public and that underwriters exercised their option in full. The capital infusion is earmarked to advance Erasca’s RAS/MAPK pathway programs and extend clinical operations; the company framed the raise as liquidity to support ongoing development rather than an expansion of pipeline strategy.